Therapeutic Inhibition of Angiogenesis

互联网2014-02-13

555

The idea of antiangiogenesis as a therapeutic strategy has been around for several decades (1 ). Vigorously pursued as a novel anticancer strategy (reviewed in (2 –6 ), it is now widely considered to be a promising approach to the treatment of a range of pathologies of which uncontrolled vascular proliferation is a component (see Table 1 ). To date, therapeutic benefit has been achieved with antiangiogenic therapy in the treatment of life-threatening infantile hemangioma, pulmonary hemangiomatosis, and in the treatment of some vascular tumors (7 ,8 ).

Table 1 Table 1

Pathologies Likely to Benefit from Therapeutic Intervention in Angiogenesis
Excess angiogenesis	Insufficient angiogenesis
Arthritis	Angiology
Inflammatory,	Vascular malformation
Rheumatoid,	Hemifacial micromia
Kaposi's sarcoma	Bone fracture nonunion
Leukemia, lymphoma, and myeloma	Chronic wounds
Macular degeneration	Ischemia/infarction
Paget's disease	Cerebral
Psoriasis	Intestinal
Retinopathy (and its vascular complications)	Myocardial
Proliferative	Peripheral
Of prematurity	Pyrogenic granuloma
Solid carcinomas	Ulcer
Primary	Duodenal
Secondary (metastasis)	Gastric
Vascular tumors
Hemangioma
Capillary
Juvenile (infantile)
Hemangiomatosis
Hemagioblastoma
Other benign vascular proliferations